Publication
Article
Specialty Pharmacy Times
Author(s):
This activity is supported by educational grants from Biogen Idec and Genzyme, a Sanofi company.
Logan E. Davis, PharmD
Director of Franchise Development
Vital Care, Inc
Meridian, Mississippi
Laura Joiner, PharmD
PGY-1 Pharmacy Resident
Vital Care of Meridian
Meridian, Mississippi
Chris Newlin, PharmD
Project Manager
Residency Program Coordinator
Vital Care, Inc
Meridian, Mississippi
Disclosures
The following faculty, planners, and staff have no relevant financial relationships with commercial interests to disclose.
Faculty
Logan E. Davis, PharmD
Laura Joiner, PharmD
Chris Newlin, PharmD
Pharmacy Times Office of Continuing Professional Education Planning Staff—Judy V. Lum, MPA, and Steve Lin, PharmD, RPh
Pharmacy Times Editorial Staff— Kirk McKay and David Allikas
An anonymous peer reviewer was part of the content validation and conflict resolution process. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Objectives
At the conclusion of this educational activity, participants should be able to complete the following:
1. Examine the epidemiology, pathophysiology, and clinical progression of multiple sclerosis (MS).
2. Evaluate current and emerging therapeutic strategies for slowing disease progression in patients with MS and for their role in the treatment paradigm.
3. Describe common adverse events associated with MS therapies, as well as strategies for mitigating these side effects.
4. Identify the role of specialty pharmacists in maximizing outcomes in patients with MS.
Target audience: Specialty pharmacists
Type of activity: Knowledge
Release date: December 12, 2013
Expiration date: December 12, 2015
Estimated time to complete activity: 1.5 hours
Fee: This lesson is offered free online at www.pharmacytimes.org. There is a nominal fee of $10.00 for mailed/faxed evaluation and exam forms.
Click here to view this activity.
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-13-166-H01-P. The activity is available for CE credit through December 12, 2015.